Determinants of Response to Talazoparib in Patients with HER2-Negative, Germline BRCA1/2-Mutated Breast Cancer

PURPOSE: PARP inhibitors (PARPi) have demonstrated efficacy in tumors with germline breast cancer susceptibility genes (gBRCA) 1 and 2 mutations, but further factors influencing response to PARPi are poorly understood. EXPERIMENTAL DESIGN: Breast cancer tumor tissue from patients with gBRCA1/2 mutat...

Descripción completa

Detalles Bibliográficos
Autores principales: Blum, Joanne L., Laird, A. Douglas, Litton, Jennifer K., Rugo, Hope S., Ettl, Johannes, Hurvitz, Sara A., Martin, Miguel, Roché, Henri H., Lee, Kyung-Hun, Goodwin, Annabel, Chen, Ying, Lanzalone, Silvana, Chelliserry, Jijumon, Czibere, Akos, Hopkins, Julia F., Albacker, Lee A., Mina, Lida A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2022
Materias:
Precision Medicine and Imaging
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9365365/
https://www.ncbi.nlm.nih.gov/pubmed/35091441
http://dx.doi.org/10.1158/1078-0432.CCR-21-2080

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9365365/
https://www.ncbi.nlm.nih.gov/pubmed/35091441
http://dx.doi.org/10.1158/1078-0432.CCR-21-2080

Ejemplares similares